nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefuroxime—Haemorrhage—Vandetanib—thyroid cancer	0.00752	0.00752	CcSEcCtD
Cefuroxime—Urinary tract disorder—Vandetanib—thyroid cancer	0.00743	0.00743	CcSEcCtD
Cefuroxime—Vaginal moniliasis—Epirubicin—thyroid cancer	0.0074	0.0074	CcSEcCtD
Cefuroxime—Urethral disorder—Vandetanib—thyroid cancer	0.00737	0.00737	CcSEcCtD
Cefuroxime—Erythema multiforme—Vandetanib—thyroid cancer	0.00711	0.00711	CcSEcCtD
Cefuroxime—Vulvovaginal candidiasis—Epirubicin—thyroid cancer	0.0071	0.0071	CcSEcCtD
Cefuroxime—Vaginal moniliasis—Doxorubicin—thyroid cancer	0.00685	0.00685	CcSEcCtD
Cefuroxime—Vulvovaginal mycotic infection—Epirubicin—thyroid cancer	0.00683	0.00683	CcSEcCtD
Cefuroxime—Angiopathy—Vandetanib—thyroid cancer	0.00683	0.00683	CcSEcCtD
Cefuroxime—Local reaction—Epirubicin—thyroid cancer	0.00675	0.00675	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00661	0.00661	CcSEcCtD
Cefuroxime—Vulvovaginal candidiasis—Doxorubicin—thyroid cancer	0.00657	0.00657	CcSEcCtD
Cefuroxime—Vulvovaginal mycotic infection—Doxorubicin—thyroid cancer	0.00632	0.00632	CcSEcCtD
Cefuroxime—Muscle spasms—Vandetanib—thyroid cancer	0.0063	0.0063	CcSEcCtD
Cefuroxime—Local reaction—Doxorubicin—thyroid cancer	0.00624	0.00624	CcSEcCtD
Cefuroxime—Vaginal discharge—Epirubicin—thyroid cancer	0.00614	0.00614	CcSEcCtD
Cefuroxime—Neutropenia—Sorafenib—thyroid cancer	0.00593	0.00593	CcSEcCtD
Cefuroxime—Cough—Vandetanib—thyroid cancer	0.00571	0.00571	CcSEcCtD
Cefuroxime—Vaginal discharge—Doxorubicin—thyroid cancer	0.00568	0.00568	CcSEcCtD
Cefuroxime—Convulsion—Vandetanib—thyroid cancer	0.00567	0.00567	CcSEcCtD
Cefuroxime—Infestation NOS—Sorafenib—thyroid cancer	0.00565	0.00565	CcSEcCtD
Cefuroxime—Infestation—Sorafenib—thyroid cancer	0.00565	0.00565	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.0056	0.0056	CcSEcCtD
Cefuroxime—Chest pain—Vandetanib—thyroid cancer	0.00558	0.00558	CcSEcCtD
Cefuroxime—Arthralgia—Vandetanib—thyroid cancer	0.00558	0.00558	CcSEcCtD
Cefuroxime—Renal failure—Sorafenib—thyroid cancer	0.00556	0.00556	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00554	0.00554	CcSEcCtD
Cefuroxime—Jaundice—Sorafenib—thyroid cancer	0.00551	0.00551	CcSEcCtD
Cefuroxime—Stomatitis—Sorafenib—thyroid cancer	0.00551	0.00551	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00535	0.00535	CcSEcCtD
Cefuroxime—Thrombocytopenia—Vandetanib—thyroid cancer	0.00523	0.00523	CcSEcCtD
Cefuroxime—Skin disorder—Vandetanib—thyroid cancer	0.00519	0.00519	CcSEcCtD
Cefuroxime—Haemoglobin—Sorafenib—thyroid cancer	0.0051	0.0051	CcSEcCtD
Cefuroxime—Haemorrhage—Sorafenib—thyroid cancer	0.00507	0.00507	CcSEcCtD
Cefuroxime—Urinary tract disorder—Sorafenib—thyroid cancer	0.00501	0.00501	CcSEcCtD
Cefuroxime—Urethral disorder—Sorafenib—thyroid cancer	0.00497	0.00497	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00487	0.00487	CcSEcCtD
Cefuroxime—Erythema multiforme—Sorafenib—thyroid cancer	0.0048	0.0048	CcSEcCtD
Cefuroxime—Dyspnoea—Vandetanib—thyroid cancer	0.00477	0.00477	CcSEcCtD
Cefuroxime—Dyspepsia—Vandetanib—thyroid cancer	0.0047	0.0047	CcSEcCtD
Cefuroxime—Decreased appetite—Vandetanib—thyroid cancer	0.00465	0.00465	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00461	0.00461	CcSEcCtD
Cefuroxime—Angiopathy—Sorafenib—thyroid cancer	0.0046	0.0046	CcSEcCtD
Cefuroxime—Immune system disorder—Sorafenib—thyroid cancer	0.00458	0.00458	CcSEcCtD
Cefuroxime—Injection site pain—Epirubicin—thyroid cancer	0.00457	0.00457	CcSEcCtD
Cefuroxime—Pain—Vandetanib—thyroid cancer	0.00457	0.00457	CcSEcCtD
Cefuroxime—Erythema—Sorafenib—thyroid cancer	0.00442	0.00442	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00437	0.00437	CcSEcCtD
Cefuroxime—Muscle spasms—Sorafenib—thyroid cancer	0.00425	0.00425	CcSEcCtD
Cefuroxime—Injection site pain—Doxorubicin—thyroid cancer	0.00423	0.00423	CcSEcCtD
Cefuroxime—Abdominal pain—Vandetanib—thyroid cancer	0.00423	0.00423	CcSEcCtD
Cefuroxime—Body temperature increased—Vandetanib—thyroid cancer	0.00423	0.00423	CcSEcCtD
Cefuroxime—Angioedema—Sorafenib—thyroid cancer	0.00404	0.00404	CcSEcCtD
Cefuroxime—Leukopenia—Sorafenib—thyroid cancer	0.00395	0.00395	CcSEcCtD
Cefuroxime—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00395	0.00395	CcSEcCtD
Cefuroxime—Creatinine increased—Epirubicin—thyroid cancer	0.00392	0.00392	CcSEcCtD
Cefuroxime—Cough—Sorafenib—thyroid cancer	0.00386	0.00386	CcSEcCtD
Cefuroxime—Pruritus—Vandetanib—thyroid cancer	0.00378	0.00378	CcSEcCtD
Cefuroxime—Arthralgia—Sorafenib—thyroid cancer	0.00376	0.00376	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00374	0.00374	CcSEcCtD
Cefuroxime—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.00374	0.00374	CcSEcCtD
Cefuroxime—Vaginal inflammation—Epirubicin—thyroid cancer	0.00374	0.00374	CcSEcCtD
Cefuroxime—Diarrhoea—Vandetanib—thyroid cancer	0.00366	0.00366	CcSEcCtD
Cefuroxime—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00365	0.00365	CcSEcCtD
Cefuroxime—Creatinine increased—Doxorubicin—thyroid cancer	0.00363	0.00363	CcSEcCtD
Cefuroxime—Salivary hypersecretion—Epirubicin—thyroid cancer	0.00363	0.00363	CcSEcCtD
Cefuroxime—Anaphylactic shock—Sorafenib—thyroid cancer	0.00361	0.00361	CcSEcCtD
Cefuroxime—Colitis—Epirubicin—thyroid cancer	0.00359	0.00359	CcSEcCtD
Cefuroxime—Candida infection—Epirubicin—thyroid cancer	0.00357	0.00357	CcSEcCtD
Cefuroxime—Dizziness—Vandetanib—thyroid cancer	0.00353	0.00353	CcSEcCtD
Cefuroxime—Thrombocytopenia—Sorafenib—thyroid cancer	0.00353	0.00353	CcSEcCtD
Cefuroxime—Blood urea increased—Epirubicin—thyroid cancer	0.00353	0.00353	CcSEcCtD
Cefuroxime—Vaginal infection—Epirubicin—thyroid cancer	0.00353	0.00353	CcSEcCtD
Cefuroxime—Aplastic anaemia—Epirubicin—thyroid cancer	0.00351	0.00351	CcSEcCtD
Cefuroxime—Skin disorder—Sorafenib—thyroid cancer	0.0035	0.0035	CcSEcCtD
Cefuroxime—Vaginal inflammation—Doxorubicin—thyroid cancer	0.00346	0.00346	CcSEcCtD
Cefuroxime—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.00346	0.00346	CcSEcCtD
Cefuroxime—Anorexia—Sorafenib—thyroid cancer	0.00344	0.00344	CcSEcCtD
Cefuroxime—Vomiting—Vandetanib—thyroid cancer	0.0034	0.0034	CcSEcCtD
Cefuroxime—Mouth ulceration—Epirubicin—thyroid cancer	0.00338	0.00338	CcSEcCtD
Cefuroxime—Rash—Vandetanib—thyroid cancer	0.00337	0.00337	CcSEcCtD
Cefuroxime—Dermatitis—Vandetanib—thyroid cancer	0.00337	0.00337	CcSEcCtD
Cefuroxime—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00336	0.00336	CcSEcCtD
Cefuroxime—Headache—Vandetanib—thyroid cancer	0.00335	0.00335	CcSEcCtD
Cefuroxime—Colitis—Doxorubicin—thyroid cancer	0.00332	0.00332	CcSEcCtD
Cefuroxime—Candida infection—Doxorubicin—thyroid cancer	0.0033	0.0033	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00328	0.00328	CcSEcCtD
Cefuroxime—Vaginal infection—Doxorubicin—thyroid cancer	0.00326	0.00326	CcSEcCtD
Cefuroxime—Blood urea increased—Doxorubicin—thyroid cancer	0.00326	0.00326	CcSEcCtD
Cefuroxime—Aplastic anaemia—Doxorubicin—thyroid cancer	0.00324	0.00324	CcSEcCtD
Cefuroxime—Dyspnoea—Sorafenib—thyroid cancer	0.00321	0.00321	CcSEcCtD
Cefuroxime—Nausea—Vandetanib—thyroid cancer	0.00317	0.00317	CcSEcCtD
Cefuroxime—Dyspepsia—Sorafenib—thyroid cancer	0.00317	0.00317	CcSEcCtD
Cefuroxime—Decreased appetite—Sorafenib—thyroid cancer	0.00313	0.00313	CcSEcCtD
Cefuroxime—Thrombophlebitis—Epirubicin—thyroid cancer	0.00313	0.00313	CcSEcCtD
Cefuroxime—Mouth ulceration—Doxorubicin—thyroid cancer	0.00312	0.00312	CcSEcCtD
Cefuroxime—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00312	0.00312	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00311	0.00311	CcSEcCtD
Cefuroxime—Hepatic function abnormal—Epirubicin—thyroid cancer	0.0031	0.0031	CcSEcCtD
Cefuroxime—Pain—Sorafenib—thyroid cancer	0.00308	0.00308	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00295	0.00295	CcSEcCtD
Cefuroxime—Thrombophlebitis—Doxorubicin—thyroid cancer	0.0029	0.0029	CcSEcCtD
Cefuroxime—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.00288	0.00288	CcSEcCtD
Cefuroxime—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00287	0.00287	CcSEcCtD
Cefuroxime—Urticaria—Sorafenib—thyroid cancer	0.00286	0.00286	CcSEcCtD
Cefuroxime—Abdominal pain—Sorafenib—thyroid cancer	0.00285	0.00285	CcSEcCtD
Cefuroxime—Body temperature increased—Sorafenib—thyroid cancer	0.00285	0.00285	CcSEcCtD
Cefuroxime—Renal impairment—Epirubicin—thyroid cancer	0.00285	0.00285	CcSEcCtD
Cefuroxime—Hypersensitivity—Sorafenib—thyroid cancer	0.00266	0.00266	CcSEcCtD
Cefuroxime—Renal impairment—Doxorubicin—thyroid cancer	0.00264	0.00264	CcSEcCtD
Cefuroxime—Pruritus—Sorafenib—thyroid cancer	0.00255	0.00255	CcSEcCtD
Cefuroxime—Blood creatinine increased—Epirubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Cefuroxime—Diarrhoea—Sorafenib—thyroid cancer	0.00247	0.00247	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00244	0.00244	CcSEcCtD
Cefuroxime—Dizziness—Sorafenib—thyroid cancer	0.00238	0.00238	CcSEcCtD
Cefuroxime—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00235	0.00235	CcSEcCtD
Cefuroxime—Eosinophilia—Epirubicin—thyroid cancer	0.00232	0.00232	CcSEcCtD
Cefuroxime—Vomiting—Sorafenib—thyroid cancer	0.00229	0.00229	CcSEcCtD
Cefuroxime—Rash—Sorafenib—thyroid cancer	0.00227	0.00227	CcSEcCtD
Cefuroxime—Dermatitis—Sorafenib—thyroid cancer	0.00227	0.00227	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00226	0.00226	CcSEcCtD
Cefuroxime—Headache—Sorafenib—thyroid cancer	0.00226	0.00226	CcSEcCtD
Cefuroxime—Bronchitis—Epirubicin—thyroid cancer	0.00225	0.00225	CcSEcCtD
Cefuroxime—Pancytopenia—Epirubicin—thyroid cancer	0.00223	0.00223	CcSEcCtD
Cefuroxime—Dysuria—Epirubicin—thyroid cancer	0.00219	0.00219	CcSEcCtD
Cefuroxime—Neutropenia—Epirubicin—thyroid cancer	0.00219	0.00219	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00218	0.00218	CcSEcCtD
Cefuroxime—Eosinophilia—Doxorubicin—thyroid cancer	0.00215	0.00215	CcSEcCtD
Cefuroxime—Nausea—Sorafenib—thyroid cancer	0.00214	0.00214	CcSEcCtD
Cefuroxime—Infestation NOS—Epirubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Cefuroxime—Infestation—Epirubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Cefuroxime—Drowsiness—Epirubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Cefuroxime—Bronchitis—Doxorubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00207	0.00207	CcSEcCtD
Cefuroxime—Pancytopenia—Doxorubicin—thyroid cancer	0.00206	0.00206	CcSEcCtD
Cefuroxime—Renal failure—Epirubicin—thyroid cancer	0.00205	0.00205	CcSEcCtD
Cefuroxime—Stomatitis—Epirubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Cefuroxime—Jaundice—Epirubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Cefuroxime—Urinary tract infection—Epirubicin—thyroid cancer	0.00203	0.00203	CcSEcCtD
Cefuroxime—Dysuria—Doxorubicin—thyroid cancer	0.00203	0.00203	CcSEcCtD
Cefuroxime—Neutropenia—Doxorubicin—thyroid cancer	0.00203	0.00203	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00202	0.00202	CcSEcCtD
Cefuroxime—Sweating—Epirubicin—thyroid cancer	0.002	0.002	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00198	0.00198	CcSEcCtD
Cefuroxime—Sinusitis—Epirubicin—thyroid cancer	0.00196	0.00196	CcSEcCtD
Cefuroxime—Agranulocytosis—Epirubicin—thyroid cancer	0.00195	0.00195	CcSEcCtD
Cefuroxime—Infestation NOS—Doxorubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Cefuroxime—Infestation—Doxorubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Cefuroxime—Drowsiness—Doxorubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Cefuroxime—Renal failure—Doxorubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Cefuroxime—Haemoglobin—Epirubicin—thyroid cancer	0.00189	0.00189	CcSEcCtD
Cefuroxime—Jaundice—Doxorubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Cefuroxime—Stomatitis—Doxorubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Cefuroxime—Urinary tract infection—Doxorubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Cefuroxime—Haemorrhage—Epirubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Cefuroxime—Hepatitis—Epirubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Cefuroxime—Sweating—Doxorubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Cefuroxime—Urinary tract disorder—Epirubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Cefuroxime—Urethral disorder—Epirubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Cefuroxime—Sinusitis—Doxorubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Cefuroxime—Agranulocytosis—Doxorubicin—thyroid cancer	0.0018	0.0018	CcSEcCtD
Cefuroxime—Erythema multiforme—Epirubicin—thyroid cancer	0.00177	0.00177	CcSEcCtD
Cefuroxime—Haemoglobin—Doxorubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Cefuroxime—Haemorrhage—Doxorubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Cefuroxime—Hepatitis—Doxorubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Cefuroxime—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Cefuroxime—Angiopathy—Epirubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Cefuroxime—Urethral disorder—Doxorubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Cefuroxime—Immune system disorder—Epirubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Cefuroxime—Chills—Epirubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Cefuroxime—Erythema multiforme—Doxorubicin—thyroid cancer	0.00164	0.00164	CcSEcCtD
Cefuroxime—Erythema—Epirubicin—thyroid cancer	0.00163	0.00163	CcSEcCtD
Cefuroxime—Flatulence—Epirubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Cefuroxime—Angiopathy—Doxorubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Cefuroxime—Muscle spasms—Epirubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Cefuroxime—Immune system disorder—Doxorubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Cefuroxime—Chills—Doxorubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Cefuroxime—Erythema—Doxorubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Cefuroxime—Agitation—Epirubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Cefuroxime—Flatulence—Doxorubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Cefuroxime—Leukopenia—Epirubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Cefuroxime—Muscle spasms—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Cefuroxime—Palpitations—Epirubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Cefuroxime—Cough—Epirubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Cefuroxime—Convulsion—Epirubicin—thyroid cancer	0.00141	0.00141	CcSEcCtD
Cefuroxime—Arthralgia—Epirubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Cefuroxime—Chest pain—Epirubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Cefuroxime—Agitation—Doxorubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
Cefuroxime—Leukopenia—Doxorubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Cefuroxime—Palpitations—Doxorubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Cefuroxime—Anaphylactic shock—Epirubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Cefuroxime—Cough—Doxorubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Cefuroxime—Convulsion—Doxorubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Cefuroxime—Thrombocytopenia—Epirubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Cefuroxime—Tachycardia—Epirubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Cefuroxime—Skin disorder—Epirubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Cefuroxime—Hyperhidrosis—Epirubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Cefuroxime—Chest pain—Doxorubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Cefuroxime—Arthralgia—Doxorubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00128	0.00128	CcSEcCtD
Cefuroxime—Anorexia—Epirubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Cefuroxime—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00123	0.00123	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Cefuroxime—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Cefuroxime—Tachycardia—Doxorubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Cefuroxime—Skin disorder—Doxorubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Cefuroxime—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Cefuroxime—Dyspnoea—Epirubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Cefuroxime—Somnolence—Epirubicin—thyroid cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Anorexia—Doxorubicin—thyroid cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Dyspepsia—Epirubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Cefuroxime—Decreased appetite—Epirubicin—thyroid cancer	0.00116	0.00116	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Cefuroxime—Pain—Epirubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00112	0.00112	CcSEcCtD
Cefuroxime—Dyspnoea—Doxorubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Cefuroxime—Somnolence—Doxorubicin—thyroid cancer	0.0011	0.0011	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Cefuroxime—Dyspepsia—Doxorubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Cefuroxime—Decreased appetite—Doxorubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Cefuroxime—Urticaria—Epirubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Cefuroxime—Pain—Doxorubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Cefuroxime—Abdominal pain—Epirubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Cefuroxime—Body temperature increased—Epirubicin—thyroid cancer	0.00105	0.00105	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00101	0.00101	CcSEcCtD
Cefuroxime—Hypersensitivity—Epirubicin—thyroid cancer	0.000982	0.000982	CcSEcCtD
Cefuroxime—Urticaria—Doxorubicin—thyroid cancer	0.000979	0.000979	CcSEcCtD
Cefuroxime—Abdominal pain—Doxorubicin—thyroid cancer	0.000975	0.000975	CcSEcCtD
Cefuroxime—Body temperature increased—Doxorubicin—thyroid cancer	0.000975	0.000975	CcSEcCtD
Cefuroxime—Pruritus—Epirubicin—thyroid cancer	0.000943	0.000943	CcSEcCtD
Cefuroxime—Diarrhoea—Epirubicin—thyroid cancer	0.000912	0.000912	CcSEcCtD
Cefuroxime—Hypersensitivity—Doxorubicin—thyroid cancer	0.000908	0.000908	CcSEcCtD
Cefuroxime—Dizziness—Epirubicin—thyroid cancer	0.000881	0.000881	CcSEcCtD
Cefuroxime—Pruritus—Doxorubicin—thyroid cancer	0.000872	0.000872	CcSEcCtD
Cefuroxime—Vomiting—Epirubicin—thyroid cancer	0.000847	0.000847	CcSEcCtD
Cefuroxime—Diarrhoea—Doxorubicin—thyroid cancer	0.000844	0.000844	CcSEcCtD
Cefuroxime—Rash—Epirubicin—thyroid cancer	0.00084	0.00084	CcSEcCtD
Cefuroxime—Dermatitis—Epirubicin—thyroid cancer	0.000839	0.000839	CcSEcCtD
Cefuroxime—Headache—Epirubicin—thyroid cancer	0.000835	0.000835	CcSEcCtD
Cefuroxime—Dizziness—Doxorubicin—thyroid cancer	0.000815	0.000815	CcSEcCtD
Cefuroxime—Nausea—Epirubicin—thyroid cancer	0.000791	0.000791	CcSEcCtD
Cefuroxime—Vomiting—Doxorubicin—thyroid cancer	0.000784	0.000784	CcSEcCtD
Cefuroxime—Rash—Doxorubicin—thyroid cancer	0.000777	0.000777	CcSEcCtD
Cefuroxime—Dermatitis—Doxorubicin—thyroid cancer	0.000777	0.000777	CcSEcCtD
Cefuroxime—Headache—Doxorubicin—thyroid cancer	0.000772	0.000772	CcSEcCtD
Cefuroxime—Nausea—Doxorubicin—thyroid cancer	0.000732	0.000732	CcSEcCtD
